Trial intelligence / Profile preview

Rivastigmine (Exelon) for dementia in progressive supranuclear palsy

2006-006166-42Phase 2Active

Sponsor
University of Tübingen
Start
Jan 2007
Modality
Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Reversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules
Countries
1
01

Overview

Phase 2, open-label, single-arm trial of rivastigmine in progressive supranuclear palsy (PSP), sponsored by University of Tübingen. Started Jan 2007; status: active.

02

Drugs

rivastigmine
03

Conditions

progressive supranuclear palsy (PSP)

Beyond the preview

Go deeper on 2006-006166-42.

Study design, results and competitive context are available in the Gosset platform where reported.

Study design & results

Available in the Gosset platform where reported.

Competitive context

Available in the Gosset platform where reported.

Bring the full picture into focus.

See how Gosset can support your research on 2006-006166-42.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call